Phase 1/2 Study of Dinutuximab/Cyclophosphamide/Topotecan/Sargramostim (GM-CSF) With or Without Iberdomide in Children With Relapsed, Refractory, or Progressive Neuroblastoma Following Prior Chemoimmunotherapy

This phase I/II trial studies the side effects and best dose of iberdomide when given together with chemoimmunotherapy drugs and to see how well it works in treating patients with neuroblastoma that has come back after a period of improvement (relapsed), that does not respond to treatment (refractory), or that is growing, spreading, or getting worse (progressive) following prior chemoimmunotherapy. Iberdomide is a cereblon-modulating agent. It works by helping the immune system kill tumor cells. Chemoimmunotherapy is chemotherapy combined with immunotherapy. Chemotherapy drugs, such as cyclophosphamide and topotecan, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with dinutuximab, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Granulocyte-macrophage colony-stimulating factors (GM-CSF), such as sargramostim, may increase the production of blood cells and may help the immune system recover from the side effects of chemotherapy. Giving iberdomide with chemoimmunotherapy may be safe, tolerable, and/or effective in treating patients with relapsed, refractory, or progressive neuroblastoma following prior chemoimmunotherapy.

Start Date01 May 2026

Sponsor / Collaborator

National Cancer Institute

NCT06896916

/ RecruitingPhase 1

Phase 1/2 Study of Etentamig in Combination With a CELMoD Agent for the Treatment of Patients With Relapsed/Refractory Multiple Myeloma

Multiple myeloma (MM) is a plasma cell disease characterized by the growth of clonal plasma cells in the bone marrow. The purpose of this study is to assess the adverse events and change in disease activity of etentamig in combination with a cereblon E3 ligase modulatory drug (CELMoD) agent in adult participants with relapsed/refractory (R/R) multiple myeloma (MM). Adverse events and change in disease state will be assessed.
Etentamig is an investigational drug being developed for the treatment of R/R MM. Study doctors put the participants in groups called treatment arms. Multiple doses of etentamig in combination with iberdomide will be explored. Each treatment arm receives a different dose of etentamig and iberdomide to determine a tolerable dose. Approximately 135 adult participants with R/R MM will be enrolled in the study in approximately 50 sites worldwide.
In phase 1 participants will receive escalating intravenous (IV) etentamig in combination with oral iberdomide. In phase 2 participants will receive IV etentamig at one of two doses in combination with oral iberdomide, as part of the approximately 129 month study duration.
There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution (hospital or clinic). The effect of the treatment will be frequently checked by medical assessments, blood tests, questionnaires and and monitoring of side effects.

Start Date07 Aug 2025

Sponsor / Collaborator

AbbVie, Inc.

NCT06348108

/ RecruitingPhase 1IIT

A Phase Ib, Multi-center, Study of Talquetamab in Combination With Iberdomide and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma

This phase I trial will evaluate the safety, side effects, and best dose of talquetamab in combination with iberdomide and dexamethasone in treating patients with multiple myeloma that has come back after a period of improvement (relapsed) or has not responded to previous treatment (refractory). There is currently a significant unmet need for patients with relapsed or refractory multiple myeloma (RRMM) who are triple class refractory and have been exposed to B-cell maturation antibody (BCMA) targeted therapy. These patients currently have limited treatment options and poor survival. Talquetamab is an FDA approved drug that can bring T-cells to the myeloma cell, resulting in myeloma cell death. Iberdomide is an investigational drug and works by targeting and destroying proteins that help myeloma cancer cells to survive. Dexamethasone is a corticosteroid, is similar to a natural hormone produced by the adrenal glands to reduce inflammation (swelling, heat, redness, and pain) and is used to in helping to treat certain types of cancer including myeloma.

Start Date28 Jul 2025

Sponsor / Collaborator

The University of California, San Francisco

[+2]

100 Clinical Results associated with Iberdomide

100 Translational Medicine associated with Iberdomide

100 Patents (Medical) associated with Iberdomide

Literatures (Medical) associated with Iberdomide

01 Jan 2026·Lancet Haematology

Iberdomide plus low-dose cyclophosphamide and dexamethasone in patients with relapsed and refractory multiple myeloma (the ICON study): a multicentre, single-arm, phase 2 trial

Article

Author: Roeloffzen, Wilfried W H ; de Ruijter, Maaike E M ; Verkleij, Christie P M ; Wegman, Jurgen ; Zweegman, Sonja ; Nijhof, Inger S ; Smits, Febe ; de Weerdt, Okke ; Nasserinejad, Kazem ; Kerstiens, Ramses ; Smit, Nina ; Mutis, Tuna ; Franssen, Laurens E ; de Kort, Elizabeth A ; van de Donk, Niels W C J ; Croockewit, Alexandra J ; Korst, Charlotte L B M ; Plattel, Wouter ; Levin, Mark-David ; van der Spek, Ellen ; van der Klift, Marjolein ; Groen, Kaz ; Westerman, Matthijs

BACKGROUND:

Iberdomide is an oral cereblon E3 ligase modulator with higher affinity to cereblon than immunomodulatory drugs, leading to improved direct anti-myeloma activity and enhanced immunostimulatory effects. We aimed to evaluate the safety and activity of iberdomide plus low-dose cyclophosphamide and dexamethasone (IberCd) in patients with relapsed and refractory multiple myeloma.

METHODS:

The ICON study is a prospective, single-arm, phase 2, open-label study conducted in eight hospitals in the Netherlands. We enrolled patients (aged ≥18 years) with relapsed and refractory multiple myeloma (lenalidomide-refractory) who had received two to four previous lines of therapy and had a WHO performance status of 0-2. Patients were treated with oral iberdomide (1·6 mg/day on days 1-21 of each 28-day cycle), oral low-dose cyclophosphamide (50 mg/day on days 1-28), and oral dexamethasone (40 mg [20 mg in patients age >75 years] once a week) until progression. All patients received thrombosis prophylaxis daily: 80 mg oral aspirin or 100 mg oral carbasalate calcium. Patients with a previous history of venous thromboembolism received only low molecular-weight heparin by subcutaneous injection. The primary endpoint was progression-free survival, defined as time from the start of treatment to the date of progression or death. Activity and safety were assessed in all patients who started treatment. This trial was registered at ClinicalTrials.gov (NCT04392037) and is ongoing.

FINDINGS:

Between Feb 17, 2021, and July 7, 2023, 61 patients were enrolled and received IberCd treatment (29 [48%] were female and 32 [52%] patients were male). The median number of previous lines of therapy was 3 (range 2-5); 52 (85%) patients were triple-class exposed and 27 (44%) had triple-class refractory disease. 50 patients discontinued study treatment, 39 of whom due to progressive disease, but all 61 patients were included in the main analysis population. After a median follow-up of 25·4 months (IQR 19·7-31·6), the median progression-free survival was 17·6 months (one-sided 95% CI 16·6-19·9). In all 61 patients, the most common grade 3-4 adverse events were neutropenia (34 [56%] patients) and infections (21 [34%] patients). Treatment-related serious adverse events were reported in 25 (41%) patients, with infections being the most common (34 [71%] of 48 serious adverse events). Treatment-related death occurred in one (2%) patient due to COVID-19.

INTERPRETATION:

IberCd is an all-oral and active combination for patients with relapsed and refractory multiple myeloma that showed clinically meaningful activity. This regimen offers a valuable treatment option for patients who have received two to four previous lines of therapy and compares favourably with other available treatments.

FUNDING:

Bristol Myers Squibb.

18 Dec 2025·BLOOD

An immunostimulatory CELMoD combination overcomes resistance to T-cell engagers caused by a high multiple myeloma burden

Article

Author: Chesi, Marta ; Meermeier, Erin W. ; Pfeffer, Kirsten ; Bergsagel, P. Leif ; Sharik, Meaghen E. ; Tafoya Alvarado, Yuliza ; Zhu, Yuan Xiao ; Stein, Caleb K. ; Du, Megan T. ; Shi, Chang-Xin

Abstract:

Bispecific T-cell engagers (TCEs) targeting B-cell maturation antigen (BCMA) and CD3, induce deep hematologic responses in ∼60% of heavily pretreated patients with multiple myeloma (MM). We and others found that high tumor burden leads to resistance to TCE and novel strategies are urgently needed to improve responses in this setting. Ikaros degraders, including immunomodulatory drugs (IMiDs) and cereblon E3 ligase modulatory drugs (CELMoDs), represent logical partners for TCEs due to their direct anti-MM effects and additional immune-stimulatory activity; however, it is unclear how to optimally combine them with TCEs. Taking advantage of the immunocompetent IMiD-sensitive Vk∗MYChCRBN murine model of MM, we optimized strategies to overcome primary resistance to BCMA-TCEs and achieve sustained remission, while maintaining a manageable safety profile. The addition of anti–programmed cell death protein 1 (PD1) and pomalidomide reduced the T-cell exhaustion that occurs in response to TCEs in high tumor burden settings. This allowed for a higher degree of T-cell activation and significant improvement in response rates but also increased risk of lethal cytokine release syndrome (CRS). To moderate the response and prevent CRS, we evaluated Ikaros degraders and dexamethasone (DEX) with step-up–dosed TCEs. Pretreatment with iberdomide and DEX reshaped the bone marrow T-cell compartment, promoted infiltration of naïve T cells, and generated 100% response rates and the longest survival in subjects with high tumor burden. This was accompanied by more favorable T-cell profiling, with limited expansion of regulatory T cells and exhaustion. Overall, administering a TCE after DEX and iberdomide treatments provided deeper and more durable responses with a reduced risk of CRS.

01 Aug 2025·JOURNAL OF MEDICAL VIROLOGY

Novel Cereblon‐Binding Immunomodulators Have Increased Potency Against Gammaherpesvirus‐ Associated Lymphomas In Vitro

Article

Author: Davis, David A. ; Shrestha, Prabha ; Treco, Emma N. ; Yarchoan, Robert

ABSTRACT:

Primary effusion lymphoma (PEL), which is caused by Kaposi sarcoma herpesvirus (KSHV), and Burkitt lymphoma (BL), a subset of which are associated with Epstein‐Barr virus (EBV), are aggressive non‐Hodgkin's lymphomas. Both have relatively poor survival compared to other lymphomas. Cereblon‐binding immunomodulators (CBIs), such as pomalidomide (Pom), show in vitro efficacy and clinical activity against certain of these lymphomas. Next generation CBIs, such as golcadomide (Golc) and iberdomide (Iber), have increased affinity to the primary cellular target, cereblon, making them potentially better anticancer agents. Here, we report the in vitro activity of these novel CBIs against PEL and BL cell lines. Both Golc and Iber, but primarily Golc, caused substantial growth suppression of PEL and BL lines with much lower half‐maximal inhibitory concentration (IC50) compared to Pom. This growth suppression was mediated, in part, by enhanced downregulation of interferon regulatory factor 4 (IRF4) in PEL cell lines. Additionally, both Golc and Iber increased immune surface markers such as ICAM‐1, B7‐2, and MHC‐I in PEL and BL cells at lower concentrations than Pom; these increases led to enhanced recognition of both PEL and BL cells by T‐cells. The novel CBIs had relatively little activity in Pom‐resistant cell lines with low levels of cereblon, suggesting that binding to cereblon is also important for the functions of the novel CBIs. These data show that the newer CBIs are more potent and effective against PEL and BL lines than Pom, and therefore, are worth investigating clinically in patients with these tumors.

News (Medical) associated with Iberdomide

11 Mar 2026

·allsci.com

BMS upbeat on protein degrader mezigdomide after Phase III results in relapsed multiple myeloma

Bristol Myers Squibb (BMS; NYSE: BMY) announced positive interim results from the SUCCESSOR-2 study, a Phase III trial evaluating oral mezigdomide in combination with carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma. The readout marks the first positive Phase III study for mezigdomide and the second for the company’s CELMoD program, a platform of next-generation cereblon-modulating protein degraders central to BMS’s hematology pipeline. SUCCESSOR-2 (NCT05552976) is a seamless Phase II/III, multicenter, randomized, open-label trial comparing mezigdomide plus carfilzomib and dexamethasone (MeziKd) against carfilzomib and dexamethasone alone (Kd) in patients with relapsed or refractory multiple myeloma previously exposed to anti-CD38 therapy and lenalidomide. The primary endpoint of the Phase III portion was progression-free survival. According to the company, MeziKd demonstrated a statistically significant and clinically meaningful improvement in PFS over Kd. Exact hazard ratios, median PFS values, and p-values were not disclosed in the topline release. Safety findings were consistent with the known profile of mezigdomide and the combination regimen, with no new signals reported. Key secondary endpoints — including overall survival, overall response rate, duration of response, MRD negativity, and health-related quality of life — will be reported at a future medical meeting. Patients continue to be followed for survival and safety. BMS stated that data will be shared with health authorities, with no specific NDA filing timeline disclosed. Cristian Massacesi, the company’s chief medical officer, said the results “reinforce the value of our CELMoD program and our targeted protein degradation platform” and “strengthen our confidence in bringing forward effective, accessible oral treatment options”. Mezigdomide is a cereblon E3 ligase modulator (CELMoD) designed to bind cereblon, a substrate receptor of the CRL4 E3 ubiquitin ligase complex, and redirect the complex to ubiquitinate and degrade the transcription factors Ikaros (IKZF1) and Aiolos (IKZF3). These proteins play key roles in the growth and survival of malignant plasma cells in multiple myeloma. By promoting their degradation, CELMoD agents enhance anti-tumor immune activity and induce myeloma cell death. The mechanism builds on the established immunomodulatory drug (IMiD) class, which includes lenalidomide and pomalidomide, therapies that have become central components of current multiple myeloma treatment regimens. Multiple myeloma remains an incurable malignancy characterized by repeated cycles of response and relapse. While treatment options for relapsed or refractory multiple myeloma (RRMM) have expanded substantially in recent years — including bispecific antibodies, CAR-T cell therapies, and antibody-drug conjugates — patients who have progressed on anti-CD38 antibodies and lenalidomide often face limited therapeutic options. In this setting, orally administered agents that can be combined with existing backbone regimens remain an important area of clinical development. The competitive landscape in RRMM spans several therapeutic modalities. Key competing assets include: Bristol Myers Squibb’s iberdomide, another CELMoD agent currently being evaluated in Phase III trials in combination with daratumumab and dexamethasone in relapsed or refractory multiple myeloma. Johnson & Johnson’s talquetamab, a bispecific antibody targeting GPRC5D and CD3 that is being evaluated in Phase III trials for relapsed disease. Pfizer’s elranatamab, a BCMA×CD3 bispecific antibody that received US FDA approval for relapsed or refractory multiple myeloma and is undergoing further Phase III evaluation. Johnson & Johnson and Legend Biotech’s BCMA-directed CAR-T therapy ciltacabtagene autoleucel, which the US FDA approved for multiple myeloma and is being studied in additional Phase III trials across earlier treatment lines. GSK’s BCMA-targeted antibody-drug conjugate belantamab mafodotin, which is being evaluated in ongoing Phase III combination studies following earlier regulatory setbacks. Mezigdomide’s oral administration and compatibility with established backbone regimens such as carfilzomib plus dexamethasone could position it as a convenient treatment option in later-line settings. However, the therapy’s eventual role in the treatment sequence will depend on the magnitude and durability of clinical benefit observed in Phase III studies relative to existing immunotherapies and cell-based approaches. Your email address will not be published. Required fields are marked * Comment * Name * Email * Website

Phase 3Clinical ResultImmunotherapyCell TherapyDrug Approval

09 Mar 2026

·www.fiercebiotech.com

BMS builds momentum for CELMoD drug after improving myeloma PFS in phase 3

BMS’ Chief Medical Officer, Cristian Massacesi, M.D., said this morning’s mezigdomide results “reinforce the value of our CELMoD program.”\n Bristol Myers Squibb’s mezigdomide has scored its first phase 3 win, with the Cereblon E3 ligase modulator (CELMoD) tied to a statistically significant improvement in progression-free survival (PFS) among multiple myeloma patients.The Successor-2 trial compared a combination of mezigdomide, Amgen’s cancer drug Kyprolis (carfilzomib), and the corticosteroid dexamethasone with carfilzomib and dexamethasone alone in patients with relapsed or refractory multiple myeloma. The oral mezigdomide regimen hit the study’s primary endpoint by demonstrating a statistically significant and clinically meaningful improvement in PFS, the company said in a March 9 release. Safety findings were “consistent with the known profile of mezigdomide and the combination regimen,” said BMS, which is continuing the study so it can assess the key secondary endpoint of overall survival.The company is holding back detailed data for a future medical conference and said it will also share the findings with health authorities.The positive mezigdomide data comes six months after BMS’ CELMoD program scored another hit when a combination of iberdomide, the approved CD38 drug Darzalex and the steroid dexamethasone met one of the dual primary endpoints in a phase 3 multiple myeloma trial. BMS’ Chief Medical Officer, Cristian Massacesi, M.D., said this morning’s mezigdomide results “reinforce the value of our CELMoD program and our targeted protein degradation platform, and strengthen our confidence in bringing forward effective, accessible oral treatment options for patients with difficult-to-treat blood cancers and potentially beyond.”William Blair analysts said they continue to believe the CELMoD program “has potential to be a key long-term growth driver” for BMS. While this morning’s data are helping build momentum for mezigdomide, they suggested that the “most strategically important readout” for mezigdomide will be a head-to-head study against BMS’ myeloma drug Pomalyst, which is expected to deliver data next year.Meanwhile, BMS is evaluating iberdomide against its own Revlimid and is expecting to read out a phase 2 study of another CELMoD drug, golcadomide, later this year.

Phase 3Clinical ResultPhase 2Phase 1

09 Mar 2026

·endpoints.news

Bristol Myers says second CELMoD succeeds in Phase 3

Bristol Myers Squibb has claimed another success from its CELMoD program. The oral protein degrader mezigdomide cleared the Phase 3 portion of an open-label study called SUCCESSOR-2 in relapsed or refractory multiple myeloma, the company said Monday . When given in combination with Amgen’s Kyprolis and the corticosteroid dexamethasone, mezigdomide demonstrated a “clinically meaningful” improvement in progression-free survival compared to patients who got only the other two treatments, BMS said. Mezigdomide is a new type of protein degrader called a cereblon E3 ligase modulator, or CELMoD. It works as a molecular glue by sticking cereblon to a disease-causing protein, leading it to be destroyed by the body. The company heralded SUCCESSOR-2 as the second positive Phase 3 study from its CELMoD program. The other late-stage entrant, iberdomide, has been submitted to the FDA for multiple myeloma, with a decision expected by Aug. 17. A Bristol Myers spokesperson said the mezigdomide results will be “shared with health authorities,” but declined to give further detail on the company’s regulatory plans. The SUCCESSOR-2 study will continue to follow patients for overall survival, a key secondary endpoint, and BMS said more data will be presented at an upcoming medical meeting. But William Blair analysts wrote in a note to investors on Monday that “the most strategically important readout for mezigdomide” is SUCCESSOR-1, a head-to-head study against BMS’ Pomalyst that is expected to read out in 2027. That study would “support franchise transition from Pomalyst,” the analysts said.

Phase 3Clinical Result

100 Deals associated with Iberdomide

External Link

KEGG	Wiki	ATC	Drug Bank
D11134	-	-	DB12101

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Refractory Multiple Myeloma	NDA/BLA	United States	Bristol Myers Squibb Co.	17 Feb 2026
Relapse multiple myeloma	NDA/BLA	United States	Bristol Myers Squibb Co.	17 Feb 2026
Multiple Myeloma	NDA/BLA	China	Bristol-Myers Squibb Pharma EEIG	29 Dec 2025
Multiple Myeloma	NDA/BLA	China	Celgene International SARL	29 Dec 2025
Hematologic Neoplasms	Phase 3	Netherlands	Celgene Corp.	26 May 2021
Smoldering Multiple Myeloma	Phase 2	United States	Bristol Myers Squibb Co.	02 Nov 2021
Aggressive B-Cell Non-Hodgkin Lymphoma	Phase 2	United States	Celgene Corp.	10 Oct 2021
Aggressive B-Cell Non-Hodgkin Lymphoma	Phase 2	Austria	Celgene Corp.	10 Oct 2021
Aggressive B-Cell Non-Hodgkin Lymphoma	Phase 2	Belgium	Celgene Corp.	10 Oct 2021
Aggressive B-Cell Non-Hodgkin Lymphoma	Phase 2	France	Celgene Corp.	10 Oct 2021

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05354557 (Tandem Meetings ASTCT and CIBMTR2026)	Phase 2	Multiple Myeloma Maintenance	15	Iberdomide 1 mg	ffieegocwo(mghjipjklf) = neutropenia (n=1), rash (n=2), and infections (n=3). renxmupiaa (cluxorybic ) View more	Positive	04 Feb 2026
NCT04392037 (ICON, Pubmed \| Lancet Haematol)	Phase 2	Relapse multiple myeloma	61	dexamethasonecyclophosphamideIberdomide + dexamethasonecyclophosphamideIberdomidehamide + dexamethasonecyclophosphamideIberdomideone (relapsed and refractory multiple myeloma)	vpbmeatxtg(elrigfhxdi) = 34% of patients experienced infections ayqcxpvesd (zzkuyromfy ) View more	Positive	01 Jan 2026
NCT05354557 (ASH2025)	Phase 2	Maintenance	15	Iberdomide 1 mg	navtxmkhlj(fuiohabrnu) = bhtjrsflst ychzucimnk (udkubylkfw ) View more	Positive	06 Dec 2025
NCT04564703 (EMN26, ASH2025)	Phase 2	Multiple Myeloma Maintenance	120	Iberdomide 0.75 mg	gvtvhyucyb(iyoqrgvfsb) = neutropenia (48% in the 0.75 mg, 58% in the 1.0 mg, and 60% in the 1.3 mg cohorts), followed by infections (8%, 18%, and 18%; mostly respiratory infections). Grade ≥3 rash was more frequent in the 1.3 mg cohort (10%), compared to 0.75 mg (0%) and 1.0 mg (3%) cohorts. There were no grade ≥3 AEs of thrombocytopenia, anemia, or venous thromboembolism. Only 1 of 120 pts (0.8%) developed grade ≥3 neuropathy (1.3 mg), and 1 (0.8%) developed grade 3 diarrhea (1.0 mg). moiazwmjpn (hsyvaurgqs )	Positive	06 Dec 2025
NCT04564703 (EMN26, ASH2025)	Phase 2	Multiple Myeloma Maintenance	120	Iberdomide 1.0 mg		Positive	06 Dec 2025
NCT05896228 (ReKInDLE, ASH2025)	Phase 2	Relapse multiple myeloma	30	Iberdomide+Carfilzomib+Daratumumab+Dexamethasone	niuphxtcbd(lkkgfgfzeg) = Grade 3 or greater events included neutropenia (50%), lymphocytopenia (40%), leukopenia (23%), thrombocytopenia (10%), and anemia (3%) but were manageable with growth factor support and/or iber dose-reduction, as needed. nksmetytlq (qzprgqvenc ) View more	Positive	06 Dec 2025
NCT02773030 (CC-220-MM-001, ASH2025)	Phase 1/2	Multiple Myeloma	75	Iberdomide plus daratumumab and dexamethasone (IberDd)	moaogkgizg(ghwdspnkyh) = llyeicbqqe jlmqlynvha (ojvhkyxmol ) View more	Positive	06 Dec 2025
NCT02773030 (CC-220-MM-001, ASH2025)	Phase 1/2	Multiple Myeloma	75	Iberdomide plus daratumumab and dexamethasone (IberDd) (No renal impairment)	moaogkgizg(ghwdspnkyh) = ezrnyrpkiy jlmqlynvha (ojvhkyxmol ) View more	Positive	06 Dec 2025
ACTRN12621001037897 (IBIS, ASH2025)	Phase 1	Multiple Myeloma	29	Iberdomide+Isatuximab+Dexamethasone	eafujbaams(rnuzorekef) = pxioatlfkn kogmaqttcx (svlenhcugp, 50.3 - 82.6) View more	Positive	06 Dec 2025
ALLG MM25 (ASH2025)	Phase 1/2	Multiple Myeloma t(11;14)	20	Venetoclax+Iberdomide+dexamethasone	tukjpyqgrx(xjdvmxupxb) = nyvybroikx wlgznialap (ktnhneajkw ) View more	Positive	06 Dec 2025
NCT04975997 (EXCALIBER-RRMM, Company_Website) Manual	Phase 3	Multiple Myeloma	664	Dexamethasone+Iberdomide+Daratumumab	tbfrxtdbpa(jgunptqmuw) = demonstrated a statistically significant improvement buobognrnp (zzkiukpsbo )	Positive	23 Sep 2025
NCT04975997 (EXCALIBER-RRMM, Company_Website) Manual	Phase 3	Multiple Myeloma	664	Dexamethasone+Daratumumab+Bortezomib		Positive	23 Sep 2025
NCT05199311 (phase 1/2 study, ASCO2025)	Phase 2	Multiple Myeloma	38	Carfilzomib, iberdomide, and dexamethasone (KID)	tdaotnjsvu(bakqhfuomv) = sihaffzcfu wobuyiborf (zqvqemfufb ) View more	Positive	30 May 2025

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis